Regeneron Pharmaceuticals (REGN) has been under the spotlight with successful results from the
Cemdisiran’s Phase 3 trial, potential revival due to drug pricing issues, and expectations of successful regulatory approvals for
Odronextamab. The company has notable transactions in its stock by
investment firms, including buying and selling of shares.
Alliancebernstein, AQR Capital, Ieq Capital, GW Henssler & Associates, and others have been reshuffling their positions in REGN. Regeneron’s stock performance has seen an upswing with its new price targets.
Positive sentiment surrounds REGN with its strategic visibility in upcoming investor conferences highlighting innovation and growth. Firm decisions by
Jefferies Financial and Guggenheim have also led to upward revisions for the company's price targets. Lastly, the FDA has extended review dates for REGN’s
EYLEA and has approved
Linvoseltamab for Multiple Myeloma. Despite a postponement of key EYLEA HD approval decisions, REGN still shows promise as an investment due to
potential growth and
innovation.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 06 Sep 2025 22:51:46 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor 3
